Cite
HARVARD Citation
Leblond, V. et al. (2017). A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. Leukemia & lymphoma. 58 (11), pp. 2615-2623. [Online].